Salute e Benessere
Proteotype Awarded £1.5 Million Grant to Advance Early Cancer Detection with Innovative Enlighten® Test
While many cancer diagnostics rely on tumour-released signals, such as circulating tumour DNA, which is often only detectable once cancer has progressed, Enlighten® takes a different and potentially more powerful approach. It measures the to tumour development, tracking changing levels of proteins that occur even in the earliest stages of cancer.
Initial results have been promising. At AACR 2024, Proteotype reported a detection rate of 86% across multiple cancers, with a 0% false-positive rate and . The test now needs to be validated in a larger group of patients, enabling a statistically powered calculation of performance.
Dr. Emma Yates , co-founder and Chief Scientific Officer at Proteotype Diagnostics, said: Enlighten®
Enlighten® will be trialled in real-world NHS settings with a specific focus on reaching higher-risk, underserved populations. The MODERNISED clinical study, led by Professor Andrew Davies from the University of Southampton Experimental Cancer Medicine Centre, will recruit 1,350 participants across Southern England , targeting cancers with high mortality rates in socio-economically deprived areas, such as colorectal, lung, and pancreatic cancers.
Wesley Sukdao , co-founder and CEO of Proteotype Diagnostics shared: " ."
Enlighten® does not require highly expensive, specialised equipment or consumables. Affordable applied to crude patient plasma enable easy scale-up for mass screening. With low data requirements and of sample measurement, it is well positioned for NHS-wide adoption.
MODERNISED will be accompanied by a to ensure it delivers clinical benefit and meets NHS financial goals.
This grant is part of a UK Government commitment of £22.5m to deliver the OLS Cancer Programme. The NIHR i4i-OLS call forms part of this programme. Over the next 24-months, Enlighten® will undergo clinical validation, bringing it closer to regulatory approval and potential integration into NHS cancer screening programs.
Professor Andrew Davies , Chief Investigator (MODERNISED), commented:
Proteotype is a pioneering diagnostics company dedicated to the development of advanced multi-cancer early detection and personalised medicine tests that measure the host response to tumour development. By leveraging cutting-edge technologies and comprehensive research, Proteotype aims to revolutionise cancer diagnostics and improve early detection, ultimately enhancing patient outcomes and survival rates.
Email invest@proteotype.com to partner and bring this test to a clinic near you.
View original content: https://www.prnewswire.co.uk/news-releases/proteotype-awarded-1-5-million-grant-to-advance-early-cancer-detection-with-innovative-enlighten-test-302271640.html